Literature DB >> 18317061

Indolent lung cancers--time for a paradigm shift: a review.

Gunnar Hillerdal1.   

Abstract

The present paradigm is that slow-growing and clinically unimportant lung cancers are very rare. Over the years, convincing evidence for their existence in significant numbers has been dismissed, but with computerized tomography scanning being increasingly common, their reality can no longer be denied. The time is now ripe for a paradigm shift--with consequences for screening as well as clinical practice in the future. The doubling time of the tumor is probably the most important factor for survival of the patient, and research on how to measure this figure is urgent. Age, smoking habits, and comorbidities of the patient are now the main factors when discussing treatment with the patient; once we can predict the behavior of the cancer, i.e., whether it is indolent or actually threatens the patient's life, we will be able to give better advice.

Entities:  

Mesh:

Year:  2008        PMID: 18317061     DOI: 10.1097/JTO.0b013e3181653ce3

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  6 in total

1.  Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe.

Authors:  Jesper Holst Pedersen; Witold Rzyman; Giulia Veronesi; Thomas A D'Amico; Paul Van Schil; Laureano Molins; Gilbert Massard; Gaetano Rocco
Journal:  Eur J Cardiothorac Surg       Date:  2017-03-01       Impact factor: 4.191

2.  Longitudinal multistage model for lung cancer incidence, mortality, and CT detected indolent and aggressive cancers.

Authors:  William D Hazelton; Gary Goodman; William N Rom; Melvyn Tockman; Mark Thornquist; Suresh Moolgavkar; Joel L Weissfeld; Ziding Feng
Journal:  Math Biosci       Date:  2012-06-15       Impact factor: 2.144

3.  Clinical Significance of Thrombelastography Results in Patients with Lung Adenocarcinoma in Situ Complicated with Type 2 Diabetes.

Authors:  Ke Chen; Qiuping Wang; Xuan Du; Jingcheng Hu; Lijuan Niu; Yingyi Zhou
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

4.  Genomic Underpinnings of Tumor Behavior in In Situ and Early Lung Adenocarcinoma.

Authors:  Jun Qian; Shilin Zhao; Yong Zou; S M Jamshedur Rahman; Maria-Fernanda Senosain; Thomas Stricker; Heidi Chen; Charles A Powell; Alain C Borczuk; Pierre P Massion
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

Review 5.  Can CT Screening Give Rise to a Beneficial Stage Shift in Lung Cancer Patients? Systematic Review and Meta-Analysis.

Authors:  Zixing Wang; Yaoda Hu; Yuyan Wang; Wei Han; Lei Wang; Fang Xue; Xin Sui; Wei Song; Ruihong Shi; Jingmei Jiang
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

Review 6.  [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].

Authors:  Yichu Lin; Donglai Chen; Qifeng Ding; Xuejuan Zhu; Rongying Zhu; Yongbing Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.